ライフサイエンスコーパス: clinical benefit

1 s that are only reasonably likely to predict clinical benefit.

2 d in order to understand how to maximise the clinical benefit.

3 pies designed to protect the PNS may provide clinical benefit.

4 concile the disconnect between drug cost and clinical benefit.

5 hown that inhibition of the PD-1 pathway has clinical benefit.

6 o their outcome has no measurable short-term clinical benefit.

7 .25), consistent with corticosteroids' known clinical benefit.

8 lation of TH2 responses might translate into clinical benefit.

9 thway could be therapeutically exploited for clinical benefit.

10 59.3% specificity to discriminate potential clinical benefit.

11 d progression if the investigator observed a clinical benefit.

12 sed FLT3-mutated AML, but yielded no overall clinical benefit.

13 asure for complication prevention due to its clinical benefit.

14 cer, emergence of acquired resistance limits clinical benefit.

15 KIs and provide an overall assessment of the clinical benefit.

16 ly to arise and may reduce the durability of clinical benefit.

17 eks for up to 60 weeks in patients who had a clinical benefit.

18 studies to allow more rapid determination of clinical benefit.

19 immune checkpoints like PD-1 and PD-L1 have clinical benefit.

20 nt fashion, are reasonably likely to predict clinical benefit.

21 ens were detectable in patients with durable clinical benefit.

22 but none have led to a clear and persistent clinical benefit.

23 translate this intriguing idea into tangible clinical benefit.

24 ey often failed to demonstrate a significant clinical benefit.

25 number alterations were not associated with clinical benefit.

26 oved for treating human cancers with durable clinical benefit.

27 onic dosing requires balancing toxicity with clinical benefit.

28 re necessary, but not always sufficient, for clinical benefit.

29 difference was not associated with improved clinical benefit.

30 women and men can also derive post-operative clinical benefit.

31 natorial anticancer strategies with improved clinical benefit.

32 oma, most patients do not experience durable clinical benefit.

33 pathway activation status as a biomarker for clinical benefit.

34 ently infected cells could have far-reaching clinical benefits.

35 late cellular functions for physiological or clinical benefits.

36 Larger studies are required to assess the clinical benefits.

37 nal and inflammatory changes has significant clinical benefits.

38 h dose level and narrow capacity to evaluate clinical benefits.

39 Precision Oncology is ultimately to lead to clinical benefits.

40 Aspirin desensitization provides long-term clinical benefits.

41 important public health benefits as well as clinical benefits.

42 n subjects have not demonstrated unequivocal clinical benefits.

43 mpounds tested in clinical trials showing no clinical benefits.

44 d fashion may be associated with significant clinical benefits.

45 initial systemic therapy is associated with clinical benefit, a critical characteristic for consider

46 l (OS), progression-free survival (PFS), and clinical benefit after 6 wk of therapy based on clinical

47 dict progression at 3 mo and 0.79 to predict clinical benefit after 6 wk of therapy.

48 activity may have a predictive value for the clinical benefit after chronic DBS that could be used to

49 nt antipsychotic drugs produce fairly robust clinical benefit against positive symptoms but typically

50 Conclusion Nivolumab provides long-term clinical benefit and a favorable tolerability profile co

51 imperative to avoid adverse effects without clinical benefit and keep costs manageable.

52 g daily for 21 days every 28 days-results in clinical benefit and manageable toxic effects.

53 We aimed to assess the clinical benefit and safety of nivolumab monotherapy in

54 The data also show the clinical benefit and safety of switching to a second TNF

55 ether, these data support both the long-term clinical benefit and tolerability of maintenance olapari

56 ated beyond progression if deriving apparent clinical benefit and tolerating study drug, at the inves

57 ndard oral PrEP formulations, but its likely clinical benefits and additional costs are unknown.

58 eaching NHAS targets would yield substantial clinical benefits and be cost-effective in both the gene

59 trials and cohort or case-control studies on clinical benefits and harms of screening vs no screening

60 Further studies should investigate clinical benefits and potential harms not identified to

61 We aimed to investigate the clinical benefits and safety of gene therapy through inf

62 validated outcome measures correlating with clinical benefit, and comprehensive information about th

63 The patient never experienced clinical benefit, and her course was complicated by the

64 isease-modifying treatments exist with clear clinical benefits, and the current best management of mi

65 Despite an unknown clinical benefit, approximately one third of elderly wom

66 Girentuximab had no clinical benefit as adjuvant treatment for patients with

67 e patients with atrial fibrillation provides clinical benefits at an incremental cost that represents

68 ll, 84 of 100 (84% [95% CI, 75%-91%]) gained clinical benefit before planned nephrectomy.

69 cancer families leads to only an incremental clinical benefit but substantially increases the complex

70 checkpoints on T cells has provided dramatic clinical benefit, but only a subset of patients exhibit

71 ites have not yielded consistent incremental clinical benefits, but have been associated with serious

72 d grafting therapies provide some adjunctive clinical benefit compared to standard non-regenerative/n

73 patients in the lowest FG category achieved clinical benefit compared to the highest (p < 0.001), wh

74 elf-expanding prosthesis provided meaningful clinical benefits compared with SAVR, with incremental c

75 ment with extrafine fixed triple therapy had clinical benefits compared with tiotropium in patients w

76 io [OR] 2.25, 95% CI 1.40-3.62; p=0.001) and clinical benefit (complete plus partial clinical success

77 (PD-L1) with atezolizumab can induce durable clinical benefit (DCB) in patients with metastatic uroth

78 atients with grass pollen allergy exhibiting clinical benefit during allergen immunotherapy (AIT).

79 progressive disease (PD) despite evidence of clinical benefit (eg, tumor flare or pseudo-progression)

80 -cell response, whereas 80% of patients with clinical benefit exhibited PD-1+ CD8 T-cell responses wi

81 apy (ERT) and allogeneic HSCT that has shown clinical benefit for adenosine deaminase-deficient (ADA-

82 tes that would indicate a clear expected net clinical benefit for anticoagulating AF patients with CH

83 of PI3K, PI3K inhibitors have yielded little clinical benefit for breast cancer patients.

84 FDNIRS-DCS methods may have clinical benefit for monitoring the evolution of GM-IVH,

85 ression to tamoxifen did not show an overall clinical benefit for ovarian suppression.

86 with synergistic activity may also result in clinical benefit for patients with advanced myeloma.

87 Further analysis will help define the clinical benefit for patients with mRCC treated with niv

88 l disease-positive ALL, and might also offer clinical benefit for patients with non-Hodgkin's lymphom

89 -CAR VSTs is safe and can be associated with clinical benefit for patients with progressive glioblast

90 ontinuously for 3 years, there is persistent clinical benefit for several years after its discontinua

91 acula, the best way to measure MPOD, and the clinical benefit for the patients.

92 er with the intracranial activity, support a clinical benefit for treatment with ceritinib in patient

93 and growth over the last three decades, its clinical benefits for cancer patients vary.

94 ty C-reactive protein (hsCRP) correlate with clinical benefits for individual patients.

95 une checkpoint blockade provides significant clinical benefits for melanoma patients.

96 results, olesoxime might provide meaningful clinical benefits for patients with SMA and, given its m

97 tion with these adaptive responses may yield clinical benefits for patients.

98 int blockade cancer immunotherapy, affording clinical benefits for the treatment of many difficult-to

99 ndings show that patients derive significant clinical benefit from a more potent ALK inhibitor after

100 g-1L in primary PCa associate with a reduced clinical benefit from abiraterone when these tumors prog

101 atory analysis, change in FVC indicated that clinical benefit from addition of acetylcysteine to pirf

102 Most patients derive clinical benefit from adrenalectomy, with younger patien

103 tricular dysfunction who derive the greatest clinical benefit from CABG are also at the greatest oper

104 Purpose The TAXYNERGY trial evaluated clinical benefit from early taxane switch and circulatin

105 ith chronic lymphocytic leukaemia to receive clinical benefit from the drug via a more convenient del

106 patients most likely to derive the greatest clinical benefit from therapy.

107 6 (making the patient less likely to derive clinical benefit from thrombectomy at arrival).

108 such patients are necessary to ensure a net clinical benefit from thromboprophylaxis.

109 ment of macrophages may further increase the clinical benefits from surgical and biopsy procedures.

110 Moreover, the demonstration of clinical benefits from the addition of ezetimibe to stat

111 Clinical benefit had not yet been confirmed for 8 indica

112 iation of any proposed primary endpoint with clinical benefit has not been conclusively demonstrated.

113 gering ventricular arrhythmias and because a clinical benefit has not been previously established in

114 coagulation outweighs the bleeding risk (net clinical benefit) has been shown to be approximately 1%

115 e confirmatory studies failed to demonstrate clinical benefit in 2 (8%), were terminated in 2 (8%), a

116 b seems to be consistently associated with a clinical benefit in a range of patient subgroups based o

117 of the inhibitory CTLA-4 pathway has led to clinical benefit in a subset of patients with metastatic

118 romoted immune modulation and provided equal clinical benefit in acute EAE in Nrf2(-/-) and WT mice,

119 ntibody bevacizumab has clearly demonstrated clinical benefit in cancer patients.

120 e, indicating that this ligand type may have clinical benefit in diseases showing defective cholinerg

121 lts provide evidence of safety and sustained clinical benefit in heart failure with preserved ejectio

122 of schizophrenia diagnosis would be of great clinical benefit in minimising the delay to clozapine tr

123 implantation of an ICD is associated with a clinical benefit in older patients and patients with com

124 This approach may mask real clinical benefit in one or the other domain with regard

125 in %ARNL may serve as an early biomarker of clinical benefit in patients treated with taxanes.

126 gehog pathway inhibitor vismodegib has shown clinical benefit in patients with advanced basal cell ca

127 uman IgG4 monoclonal antibody that has shown clinical benefit in patients with asthma.

128 therapy for metastatic colorectal cancer has clinical benefit in patients with colorectal liver metas

129 We demonstrate that GO lacks clinical benefit in patients with low CD33 expression bu

130 s not been demonstrated to be of substantial clinical benefit in patients with prostate cancer.

131 as well tolerated and demonstrated promising clinical benefit in patients with refractory, progressiv

132 sion Cabozantinib demonstrated a significant clinical benefit in PFS and ORR over standard-of-care su

133 t host modulation therapy may also result in clinical benefit in smokers.

134 but does not seem to provide an incremental clinical benefit in terms of functional outcomes.

135 randomized studies to evaluate and prove the clinical benefit in terms of survival and quality of lif

136 lated adverse event could be associated with clinical benefit in the context of pembrolizumab treatme

137 Met inhibition showed clinical benefit in this model.

138 approved for BRAF-positive melanoma, showed clinical benefit in three patients with BRAF(V600E)-posi

139 HBAT was safe and provided clinical benefit in treated patients.

140 Preliminary data suggested a clinical benefit in treating out-of-hospital cardiac arr

141 daily for 14 days every 21 days) resulted in clinical benefit in WD/DDLS but moderate hematologic tox

142 our knowledge its safety and other long-term clinical benefits in a large, population-based cohort ar

143 tic modalities, which have already generated clinical benefits in an important number of cancer patie

144 poly(ADP-ribose) polymerases (PARPs) elicits clinical benefits in cancer therapy.

145 e complement protein C5 and shows remarkable clinical benefits in certain complement-mediated disease

146 interfere with BCR signaling and demonstrate clinical benefits in nearly all patients.

147 to determine whether levothyroxine provided clinical benefits in older persons with this condition.

148 ftor/ivacaftor combination therapy has shown clinical benefits in patients with cystic fibrosis homoz

149 it culminating in IL-2 production could have clinical benefits in settings in which diminished Tr cel

150 thway hold promise for even more substantial clinical benefits in the future.

151 ibitor, to statin therapy has recently shown clinical benefits in the Improved Reduction of Outcomes:

152 Marked clinical benefit, including the restoration of independe

153 Because the clinical benefits induced by transplantation in this pat

154 N: Nivolumab monotherapy provided meaningful clinical benefit, irrespective of PD-L1 expression, and

155 ation that improved sensitivity provides any clinical benefit is lacking.

156 If clinical benefit is proven, then the cost-effectiveness

157 t Scale (MCBS) measure similar constructs of clinical benefit is unclear.

158 mmendations, suggest different constructs of clinical benefit measured.

159 urvival and mortality are some of the common clinical benefit measures incorporated into CEA.

160 rapy in Parkinson disease (PD) is to provide clinical benefit mediated by graft survival with nigrost

161 ional imaging and/or physician discretion of clinical benefit; NaF imaging was not used for clinical

162 inhibitors or ischemic time might modify any clinical benefits observed with aspiration thrombectomy

163 analyses are needed to establish whether the clinical benefits observed with switching to nilotinib a

164 The clinical benefit of (18)F-FDG PET was determined using d

165 r study is warranted to assess the potential clinical benefit of a reduction in swelling by intraveno

166 The clinical benefit of adding FMS-like tyrosine kinase-3 (F

167 rent GBM patients demonstrated the potential clinical benefit of adoptive T-cell therapy (ATCT) of CM

168 ive fitness as a critical determinant of the clinical benefit of AT.

169 These data confirm the clinical benefit of cobimetinib combined with vemurafeni

170 rovides a likely explanation for the limited clinical benefit of CombiDT in this setting.

171 The clinical benefit of COR was documented by a significant

172 The clinical benefit of cowhage and histamine skin provocati

173 The clinical benefit of FLT3 inhibitors in patients with acu

174 orts have systematically examined safety and clinical benefit of HBAT among botulism patients.

175 the upper range of CrCl, the safety and net clinical benefit of HDER compared with warfarin are cons

176 Antibiotics inhibited the clinical benefit of ICIs in patients with advanced cance

177 Although the clinical benefit of interleukin-2-receptor antibody (IL-

178 The clinical benefit of lowering LDL-C levels may therefore

179 g cardiovascular events, suggesting that the clinical benefit of lowering LDL-C may depend on how LDL

180 The comparative clinical benefit of nonstatin therapies that reduce low-

181 th chronic spontaneous urticaria and for the clinical benefit of patients with bullous pemphigoid.

182 e numerous randomized controlled trials, the clinical benefit of pharmacologic thromboprophylaxis for

183 Q2) What is the clinical benefit of prolonging DAPT up to 18 to 48 month

184 statistically significant but small relative clinical benefit of ranibizumab compared with bevacizuma

185 ntrol of TNF-induced cell death, and suggest clinical benefit of RIPK1 inhibitors in TNF-driven human

186 Although the clinical benefit of screening for intracranial aneurysm

187 The clinical benefit of sorafenib in patients with hepatocel

188 ve been described that have demonstrated the clinical benefit of such alloreactivity of the donor-der

189 assess safety, immunogenicity, and possible clinical benefit of the CMVPepVax vaccine in patients un

190 To show the potential clinical benefit of this technique, it was retrospective

191 However, the clinical benefit of using, for example, (18)F-NaF PET/CT

192 In end-stage renal failure, the net clinical benefit of VKAs in dialysis-dependent patients

193 rials in breast cancer have demonstrated the clinical benefits of adjuvant endocrine therapy (AET) in

194 Yet clinical benefits of antioxidant treatment for these dis

195 These findings have implications for clinical benefits of aspirin desensitization in aspirin-

196 Metaanalyses failed to demonstrate clinical benefits of beta lactam plus aminoglycoside com

197 We review the evidence supporting the clinical benefits of CIEDs, including effectiveness in e

198 omorbidity does not appear to compromise the clinical benefits of CRT-D compared with ICD alone.

199 thalamic nucleus have been implicated in the clinical benefits of deep brain stimulation for Parkinso

200 ter deep brain stimulation implantation, the clinical benefits of each contact were determined.

201 al to change clinical practice, although the clinical benefits of early surgery require confirmation

202 To maximize clinical benefits of genetic screening of patients with

203 The clinical benefits of HIV-1 non-nucleoside reverse transc

204 aimed to provide conclusive results for the clinical benefits of hyperbaric oxygen in patients with

205 population-health impact in addition to the clinical benefits of immediate initiation.

206 thrombotic events as well as on the possible clinical benefits of inhibitors of carbonic anhydrase en

207 These studies demonstrated the clinical benefits of nepafenac 0.3% over vehicle in redu

208 RATIONALE: Clinical benefits of reperfusion after myocardial infarc

209 The clinical benefits of RKF preservation strategies on mort

210 We provide evidence for the clinical benefits of stepping up patients with COPD from

211 In addition, the clinical benefits of sublingual immunotherapy might pers

212 e of neprilysin as a biotarget and weigh the clinical benefits of synthetic neprilysin inhibitors, ei

213 D6/TLS in platinum drug tolerance and reveal clinical benefits of targeting RAD6 with SMI#9 for manag

214 xel cycles administered to patients deriving clinical benefit on Mainsail was an independent prognost

215 Most BCC patients experience significant clinical benefit on vismodegib, but some develop resista

216 were not associated with daclizumab-related clinical benefit or cutaneous adverse events.

217 However, the clinical benefits or the impact on resistance of these i

218 0.95 per extra year, 0.93-0.98; p<0.001) and clinical benefit (OR 0.95 per extra year, 0.92-0.98; p=0

219 Early antiviral treatment has the greatest clinical benefit; otherwise, management includes adheren

220 persistent fluid, 2q4 may provide additional clinical benefit over 2q8 or Rq4.

221 n, folding, and/or gating) may show improved clinical benefit over available low-efficacy monotherapi

222 IIV-HD is likely to provide clinical benefit over IIV-SD irrespective of previous-se

223 h IVT before MT does not appear to provide a clinical benefit over MT alone.

224 ethylene glycol does not appear to offer any clinical benefits over polyethylene glycol alone in the

225 -L1 positivity enriches for populations with clinical benefit, PD-L1 testing alone is insufficient fo

226 However, EGFR targeting exerts only marginal clinical benefits, possibly due to activation of compens

227 The net clinical benefit (primary efficacy and safety end point)

228 recruited, 100 patients were assessable for clinical benefit prior to planned nephrectomy; 80 of 104

229 The magnitude of the clinical benefits produced by inhibitors of the renin-an

230 , some drugs have been approved with limited clinical benefit, raising concerns about setting a minim

231 e response rate (31% vs 0%; P = .04) but not clinical benefit rate (44% vs 45%; P > .99).

232 Best overall response (BR) and clinical benefit rate (CBR) were assessed across subgrou

233 6.0 months (95% CI, 4.8 to 8.3 months); and clinical benefit rate (complete response + partial respo

234 as 8.9 (95% CI, 6.1 to 11.3) months, and the clinical benefit rate (complete response + partial respo

235 otherapy yields a response rate of 24% and a clinical benefit rate (CR/PR/SD > 6 months) of 44%, high

236 Overall clinical benefit rate (stable > 6 months [n = 7] or part

237 h an objective response rate (ORR) of 4% and clinical benefit rate of 21%.

238 oma treated on phase I clinical trials had a clinical benefit rate of 36% and RMH score predicted sur

239 stable disease for at least 6 months, for a clinical benefit rate of 40%.

240 Clinical benefit rate was 36% (95% confidence interval 2

241 Outcomes of interest included best response, clinical benefit rate, progression-free survival (PFS) a

242 in device use, a clear understanding of the clinical benefits relative to costs is essential for bot

243 Exploiting cancer metabolism for clinical benefit requires defining the pathways that are

244 Six patients achieved clinical benefit responses (defined as minimal response

245 ety for Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale (MCBS) measure similar constructs

246 The primary endpoint was clinical benefit; secondary endpoints were objective res

247 omplex-1 (mTORC1) with rapamycin can provide clinical benefit, targeting downstream enzymes has the p

248 in such markers were better correlated with clinical benefit than alterations of allergen-specific C

249 en and men and appeared to offer greater net clinical benefit than clopidogrel.

250 ramme produces greater weight loss and other clinical benefits than a 12-week programme and, although

251 tion receptor agonists continue to show more clinical benefits than the traditional IFN therapy, our

252 d rapid, deep, and durable responses, with a clinical benefit that extended to patients with stable d

253 Together the findings may signal a clinical benefit that invites further investigation.

254 Although JAK2 inhibitors provide substantial clinical benefit, their disease-modifying activity is li

255 ical application, this biosensor will enable clinical benefit through early disease detection, and be

256 IPLA imparted no clinical benefit to children undergoing acute laparoscop

257 in a subset of patients who derived extended clinical benefit to dacomitinib (P = 0.04).

258 gle-agent immunotherapy has achieved limited clinical benefit to date in patients with pancreatic duc

259 he only effective treatment for long-lasting clinical benefit to IgE-mediated allergic diseases, but

260 not identify a gene signature predictive of clinical benefit to MAGE-A3 immunotherapeutic.

261 Whether such guided therapy is of clinical benefit to patients has been a source of contro

262 k group, n=202), and it provided greater net clinical benefit to patients than did considering them a

263 th chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic

264 phocytic leukemia (CLL) provides significant clinical benefit to patients, mainly by blocking adhesio

265 e oncolytic virus candidate that may provide clinical benefit to patients.

266 , as well as the apparent lack of additional clinical benefit to the rituximab-lenalidomide doublet,

267 bility for the WiSE-CRT system, and provided clinical benefits to a majority of patients within an ot

268 The consumption may also offer clinical benefits to improve insulin resistance.

269 ET-dependent chromatin signaling may provide clinical benefits to patients suffering from asthma.

270 is safe and provide indications of possible clinical benefits, to be confirmed in upcoming clinical

271 ) is a research method used to determine the clinical benefit-to-cost ratio of a given intervention.

272 s existing endocrine agents may provide some clinical benefit towards reducing and managing BM.

273 d immune-related signatures correlating with clinical benefit using a learn-and-confirm paradigm base

274 omes and Measures: The primary end point was clinical benefit (using Response Evaluation Criteria in

275 s in therapy, the magnitude and dimension of clinical benefits vary widely, and there may be reasons

276 The prospect of substantial clinical benefits warrant testing in a phase 2 trial.

277 At 3 months, this clinical benefit was accompanied by a reduction in ASM a

278 ents received afatinib plus vinorelbine, and clinical benefit was achieved in 2 of 4 trastuzumab-trea

279 Clinical benefit was achieved in 31 patients treated for

280 patients treated with afatinib monotherapy, clinical benefit was achieved in 9 patients (35%), 0 of

281 xel cycles administered to patients deriving clinical benefit was an independent prognostic factor fo

282 Clinical benefit was associated with duration of prior B

283 allergy improved safety, but no significant clinical benefit was detected.

284 The clinical benefit was evident in patients with epithelioi

285 Clinical benefit was lower in patients with de-novo Thr7

286 Clinical benefit was observed in those with ESR1 amplifi

287 This study sought to determine whether this clinical benefit was sustained over time.

288 Clinical benefits were associated with symptom self-repo

289 Clinical benefits were evaluated by the analysis of tota

290 ork is needed to understand why there was no clinical benefit when a difference in virological outcom

291 undle branch block morphology did not derive clinical benefit with CRT-D during long-term follow-up.

292 These results provide evidence of clinical benefit with dabrafenib plus trametinib and sup

293 rant myelofibrosis might achieve significant clinical benefit with fedratinib, albeit at the cost of

294 t be met that will be discussed: evidence of clinical benefit with minimal harm, standardized interpr

295 ontinued for as long as the patients derived clinical benefit with reductions in dose and frequency o

296 Conclusion There was no evidence of further clinical benefit with the addition of onartuzumab to bev

297 munostimulatory antibody, appears to provide clinical benefit without added clinically significant to

298 the treating investigators derived apparent clinical benefit without compromising safety.

299 r (LV-w1.6 WASp) has resulted in significant clinical benefit without inducing selection of clones ha

300 ventional treatments demonstrate only modest clinical benefits without lesion reversal.